findmyKOL

John Dipersio, MD

Enriched profile

Virginia E. and Sam J. Golman Professor of Medicine; Section Director, Cellular Therapy, Division of Oncology; Director, Center for Gene and Cellular Immunotherapy; Deputy Director, Siteman Cancer Center · Washington University School of Medicine

ORCIDNPI
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyMedical OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1994–2026

John Dipersio is Virginia E. and Sam J. Golman Professor of Medicine; Section Director, Cellular Therapy, Division of Oncology; Director, Center for Gene and Cellular Immunotherapy; Deputy Director, Siteman Cancer Center at Washington University School of Medicine. OpenAlex indexes 1,368 publications with 98,282 citations (h-index 127); ClinicalTrials.gov lists 27 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

John F. DiPersio, MD, is Virginia E. and Sam J. Golman Professor of Medicine at Washington University School of Medicine, St. Louis, MO. The public record shows 1,368 publications with 98,282 citations (h-index 127), centered on Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Multiple Myeloma Research and Treatments. It also documents an investigator role on 27 registered clinical trials, industry payments reported by 14 companies, 14 NIH-funded awards (1994–2026).

  • Most recent indexed publication: 2026 · Clinical cancer research
  • Top research focus: Acute Myeloid Leukemia Research
  • 27 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)11 trialsMultiple Myeloma8 trialsLeukemia, Myeloid, Acute8 trialsMDS / MPN5 trialsLymphoma4 trialsLymphoma, Non-Hodgkin2 trialsHodgkin Disease2 trialsGraft vs Host Disease2 trialsCOVID-192 trialsLymphoma, B-Cell2 trialsLeukemia, Lymphoid1 trialVomiting1 trialNausea1 trialHematologic Neoplasms1 trialLymphoma, Follicular1 trialLymphoma, Large B-Cell, Diffuse1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialAnemia, Sickle Cell1 trialRecurrence1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Drugs & molecules

across trials, industry payments and publications
ImetelstatClinical trialsIndustry payments4PublicationsCasgevygeneric · Exagamglogene autotemcelClinical trialsIndustry payments3PublicationsAdcetrisgeneric · Brentuximab vedotinClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Washington University School of MedicineClinical trials17Industry paymentsVertex Pharmaceuticals IncorporatedClinical trialsIndustry payments8Geron CorporationClinical trialsIndustry payments4

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,368publications

Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.

98,282citations

Total citations across indexed works.

127h-index

Hirsch index (OpenAlex). i10-index 507.

Clinical & industry

trials, payments and federal funding
27clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
14NIH grants · 1994–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 27 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    45.6%
    Other antiemetics37.2%
    Fosaprepitant100%
    Part B, office-administered15 patients
    Serotonin-3 Receptor Antagonist5.3%
    Palonosetron hcl97%Ondansetron Hcl3%
    Part D + Part B<11 patients
  • Cancer & immunology

    36.2%
    PD-1 inhibitor32.2%
    Pembrolizumab100%
    Part B, office-administered11 patients
    Kinase inhibitor3%
    Jakafi64%Calquence17%Iclusig10%Imbruvica10%
    Part D<11 patients
  • Sensory organs

    8.9%
    Corticosteroid8.3%
    Dexamethasone sodium phosphate100%
    Part B, office-administered36 patients
    Fluoroquinolone Antibacterial0.6%
    Ciprofloxacin Hcl100%
    Part D21 patients
8 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)4.9% facility · 95.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

14 NIH research awards on record, funded 19942026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

171 congress contributions (2005–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Other

    johndipersiolab.com/dr-john-dipersio

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →johndipersiolab.com
  • Doximity

    doximity.com/pub/john-dipersio-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/p/DZsIiRKIFSa

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Hematology

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • Board Certified

    Medical Oncology

    1987
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • Board Certified

    Internal Medicine

    1984
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • MD/PhD in Microbiology

    University of Rochester

    1980
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • BA in Biology

    Magna Cum Laude, Williams College

    1973
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu

Editorial & leadership roles

journal and society appointments
  • President

    Society of Hematologic Oncology (SOHO), 2025-2026

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sohoinsider.com
  • Former President

    American Society for Transplantation and Cellular Therapy (ASBMT), 2018-2019

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • Associate Editor

    Williams Textbook of Hematology, 11th Edition

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
4 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Faculty

    Department of Pathology & Immunology, Washington University School of Medicine (Professor, Medicine listing)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pathology.wustl.edu

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.